Autoplaque vs cmAngio®
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if you require detailed, quantitative analysis of coronary plaques and luminal stenoses directly from CT angiography images. This tool is ideal for clinicians focused on precise heart attack risk prediction and guiding treatment strategies based on comprehensive coronary artery assessment.
View Autoplaque →Choose cmAngio® if…
Choose cmAngio® if you aim to leverage existing mammography data for opportunistic screening of cardiovascular risk, particularly in women. This AI software is best suited for identifying Breast Arterial Calcifications (BAC) to provide early insights into a patient's cardiovascular health without requiring additional radiation or procedures.
View cmAngio® →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | cmAngio® |
|---|---|---|
| Pricing | Unknown | Paid, out-of-pocket |
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | Cloud-based, integrates with any DICOM-compliant viewer |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®cmAngiou00ae offers a cloud-based deployment model and is compatible with any DICOM-compliant viewer, facilitating quick and easy installation and integration into existing clinical workflows. Autoplaque, while compatible with DICOM-compliant systems, is workstation-based, which may require more specific hardware and setup.
Clinical Value
AutoplaqueAutoplaque provides direct, quantitative analysis of coronary plaques and luminal stenoses from CT angiography, offering precise data for heart attack risk prediction and treatment guidance, backed by extensive peer-reviewed research and multicenter clinical validation. While cmAngiou00ae offers valuable cardiovascular risk insights from mammograms, Autoplaque's direct quantification of coronary artery disease provides more immediately actionable clinical guidance for CAD management.
Pricing & Value
cmAngio®Both tools have undisclosed pricing. However, cmAngiou00ae explicitly mentions 'Limited-time offers for no-cost implementation and service may be available,' suggesting a potential for better value or at least more transparency around cost-saving opportunities. Autoplaque provides no such indication regarding its pricing or potential cost benefits.
Enterprise Readiness
cmAngio®cmAngiou00ae explicitly states it is HIPAA-compliant and cybersecure, and offers contact for Business Associate Agreement (BAA) details, demonstrating clear readiness for enterprise healthcare environments. Its cloud-based deployment also simplifies large-scale implementation. Autoplaque lacks explicit statements regarding HIPAA compliance or BAA availability in the provided information.
Innovation
cmAngio®cmAngiou00ae innovates by leveraging routinely acquired mammograms to detect Breast Arterial Calcifications (BAC), providing new cardiovascular risk insights without additional radiation or procedures, effectively offering a 'two-for-one' screening benefit. While Autoplaque provides advanced quantitative plaque analysis, cmAngio's ability to extract new, critical health information from existing data for a broad patient population represents a highly impactful innovation in preventative care.
Support & Docs
TieNeither tool provides comprehensive details on ongoing support or extensive documentation in the available facts or search results. While cmAngiou00ae mentions 'quick and easy installation,' implying some initial setup guidance, there is insufficient information to distinguish either product's commitment to ongoing customer support or documentation quality.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | cmAngio® |
|---|---|---|
| Name | Autoplaque | cmAngiou00ae |
| Company | Cedars-Sinai Medical Center: AIM | CureMetrix |
| Primary Clinical Focus | Quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | Detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. |
| Input Imaging Modality | CT Angiography images | Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams |
| Key Analysis/Output | AI-powered quantitative analysis of atherosclerotic plaque; Measurement of luminal stenoses; Automated vessel, plaque, and lumen segmentation | AI-based detection of Breast Arterial Calcifications (BAC); Visualization of BAC location on a scorecard |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and cmAngio®.